Table 1.
Cost and number of quality-adjusted life years (QALYs) of “dominant” individualized interventions.
| Disease | Gene | Cost of intervention | Number of QALYS | Reference++ | ||
|---|---|---|---|---|---|---|
| W/o PGx test/test 1 | With PGx test/test 2 | W/o PGx test/test 1 | With PGx test/test 2 | |||
|
Advanced adenocarcinoma
of the lung |
EGFR | SG$47,100 | SG$44,700 | 0.87 | 0.91 | (Lee et al., 2014) |
| Colorectal cancer | KRAS | ¥3,160,000($35,000) | ¥2,600,000 ($29,000) | 0.48 | 0.49 | (Sun et al., 2013) |
| UGT1A1 | $13,058 | $12,786 | 1.6347 | 1.6349 | (54) | |
| Acute coronary syndrome | CYP2C19 | $15,800 | $14,900 | 0.966 | 0.9665 | (Jonsson, 2009) |
| NZ$85,342 | NZ$84,646 | 8.544 | 8.650 | (Hess et al., 2015) | ||
| $76,906* (CLO) | $76,450 | 7.4381 | 7.5301 | (47) | ||
| $78,296 (P2Y12) | ||||||
| Neonatal diabetes | KCNJ11, ABCC8 | $71,784 | $59,256 | 16.29 | 16.99 | (Song and Chung, 2011) |
| Atrial fibrillation | 4q25 | Cost saving of $250,689 | Net gain of 8.8 | (Riewpaiboon, 2014) | ||
| Familial adenomatous polyposis | APC | €13,928.82 (Spain) | €8,038.93 | 19.92 | 19.93 | (65) |
| Neovascular macular degeneration | CFH, ARMS2/HTRA1, C3, C2, CFB | Cost saving of $493 | Gain of 0.0392 | (78) | ||
| Venous thromboembolism | Thrombo inCode® | €1,366.30–€2,795.61 (Spain) | €832.58–€848.38 | 8.2586–8.4784 | 8.5871–8.5874 | (61) |
| Breast cancer | MammaPrint® | €17,869+ (Spain) | €16,989 | 18.131 | 18.357 | (Snyder et al., 2014) |
| $27,882+ | $21,598 | 7.364 | 7.461 | (53) | ||
*Currency used is different from the currency of the country in which the corresponding economic evaluation study was carried out. Researchers chose to express costs in US $ ($). +Cost of individualized intervention including Oncotype DX®. PRA, prasugrel; CLO, clopidogrel; P2Y12, other P2Y12 inhibitor (individualized interventions including prasugrel, clopidogrel and other P2Y12 inhibitors, respectively). ++Identification number of the article ( Supplementary Table 1 ).